Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. Innovators to watch from TLA’s HealthTech Innovator conference
  2. Unlocking cell-free protein synthesis: biotech’s next big ticket?
  3. Can AI reveal complex patterns in biological data?
  4. Visualising biologics discovery: dealing with complex data
  5. ASGCT 2018: electroporation-mediated gene delivery for coronary artery disease

Latest Content

Innovators to watch from TLA’s HealthTech Innovator conference

Tech London Advocates and the Health Foundry organised the HealthTech Innovator conference which showcased promising companies working in the pharmaceutical field, whcih are launching new products and are seeking investment. Here is our round-up of the most exciting companies who presented at the event.

Telstar Presents Versatile Process Analyser Lyosensing

Lyosensing is an in-line process analyser based on the application of a quadrupole mass spectrometer system, a non-invasive technique capable of performing quantitative real-time measurements during freeze-drying processes. 

Can AI reveal complex patterns in biological data?

Can artificial intelligence be used to extract genomic data and discover relevant biomarkers? Immune-focused AI technology company CytoReason thinks so. Sally Turner finds out more from co-founder and president David Harel, including how scientists were able to predict who will respond to anti-TNF drugs such as Remicade.

Weibel CDS: Safer, Easier, and Faster Drug Delivery

At the Advanced Technologies and Treatments for Diabetes (ATTD) congress in Paris, Weibel CDS showcased a presentation demonstrating its patient-centric drug delivery products, which help reduce contamination, handling errors, and needle stick injuries when administering injectable drugs.

Phase IIIa Clinical Trial of Oral Semaglutide Completed

Novo Nordisk has announced it has completed the second Phase IIIa trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilises Emisphere Technologies' proprietary Eligen® Technology.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top